In a study, MEK inhibitors such as trametinib were shown to restore the induction of CXCL9 and 10 when treated with the platinum salt and pemetrexed doublet, resulting in a reduced tumor progression and increased survival. The gene discussed is CXCL9; the disease is neoplasm.